epoetin alfa
- Generic Name
- epoetin alfa
Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia
- Conditions
- Knee ArthropathyAnemia of Chronic DiseaseHip ArthropathyAnemia, Iron Deficiency
- Interventions
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 4
- Registration Number
- NCT03528564
- Locations
- 🇨🇦
St. Michael's Hosptial, Toronto, Ontario, Canada
Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents
- Conditions
- Dialysis-Dependent Chronic Kidney DiseaseAnemia
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT03140722
- Locations
- 🇺🇸
Research Site, Norfolk, Virginia, United States
PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns
- Conditions
- Hypoxic-Ischemic Encephalopathy
- Interventions
- Drug: Normal saline
- First Posted Date
- 2017-03-14
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 313
- Registration Number
- NCT03079167
- Locations
- 🇦🇺
Flinders Medical Centre, Bedford Park, South Australia, Australia
🇦🇺The Royal Women's Hospital, Parkville, Victoria, Australia
🇸🇬KK Women's and Children's Hospital, Singapore, Singapore
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 105
- Registration Number
- NCT03029247
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Generation of Positive Biological Samples to Epoetin for Doping Control.
- Conditions
- There Are no Conditions Under Study. Healthy Volunteers
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2017-10-05
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 2
- Registration Number
- NCT02920372
Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients
- Conditions
- AnemiaChronic Kidney Disease
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Andrea L Woodland
- Target Recruit Count
- 50
- Registration Number
- NCT02817555
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 305
- Registration Number
- NCT02652806
- Locations
- 🇨🇳
The First Affiliated hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
- Conditions
- Chronic Renal FailureAnemiaDialysis
- Interventions
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02586402
- Locations
- 🇨🇳
Changzheng Hospital, Shanghai, Shanghai, China
Cross Iron (Comparative Randomized Oral Versus Systemic IRON)
- Conditions
- Allogenic TransfusionPerioperative AnaemiaKnee ArthroplastyHip Arthroplasty
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 100
- Registration Number
- NCT02496377
- Locations
- 🇫🇷
Hôpital Lapeyronie - Département Anesthésie Réanimation A, Montpellier, France
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
- Conditions
- AnemiaEnd Stage Renal Disease (ESRD)
- Interventions
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 838
- Registration Number
- NCT02278341
- Locations
- 🇵🇱
Site PL48002, Katowice, Poland
🇭🇷Site HR38509, Zagreb, Grad Zagreb, Croatia
🇭🇷Site HR38505, Karlovac, Croatia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.